• Dual Recombinase Tracing Disproves Postnatal Neo-oogenesis i

  2026-05-04

  Xie, Zhou, and Zheng’s study introduces a robust dual recombinase-mediated genetic tracing system to test for postnatal oocyte formation in mice. Their evidence demonstrates that new oocytes do not originate after birth, even following chemically induced ovarian injury, refining foundational assumptions of mammalian reproductive biology.

• SU 5402 in Precision Signal Modulation: From Myeloma to Neur

  2026-05-04

  Explore how SU 5402 enables precise receptor tyrosine kinase inhibition in multiple myeloma and advanced neuronal systems. This article reveals unique assay strategies, mechanistic insights, and evolving applications beyond current literature.

• Clathrin-Mediated Entry of Grass Carp Reovirus: Inhibitor In

  2026-05-03

  Wang et al. (2018) clarify the entry mechanism of type III grass carp reovirus (GCRV104), demonstrating a reliance on clathrin-mediated, dynamin- and pH-dependent endocytosis. Their rigorous inhibitor analysis defines key host pathways necessary for infection, offering a foundation for future antiviral approaches and cellular entry studies.

• Vitamin D/VDR Drives Endometrial Decidualization via Estroge

  2026-05-02

  This study demonstrates that vitamin D, through its receptor VDR, directly enhances human endometrial stromal cell (ESC) decidualization by modulating both estrogen signaling and key decidualization markers. The findings clarify the molecular crosstalk between vitamin D and steroid hormone regulation in endometrial receptivity, with implications for infertility research and endometriosis models.

• PP2A Regulation of C. albicans Biofilm Resistance via Autoph

  2026-05-02

  This study reveals that protein phosphatase 2A (PP2A) regulates autophagy-related protein phosphorylation, influencing biofilm formation and antifungal drug resistance in Candida albicans. The findings identify PP2A-driven autophagy as a pivotal mechanism underlying persistent biofilm-associated infections and suggest new avenues for antifungal therapy optimization.

• AG-490 (Tyrphostin B42): Precision Modulation of JAK2/STAT6

  2026-05-01

  Explore how AG-490 (Tyrphostin B42) delivers targeted inhibition of JAK2/STAT6 signaling, with unique insights into macrophage polarization in cancer research. This article offers a protocol-driven, mechanistic perspective distinct from current resources.

• Toremifene vs Tamoxifen: Systematic Evidence in Advanced Bre

  2026-04-30

  This Cochrane systematic review rigorously compares the efficacy and safety of toremifene and tamoxifen in advanced breast cancer. It synthesizes randomized controlled trials to clarify whether these selective estrogen receptor modulators differ in therapeutic outcomes or adverse event profiles, guiding future clinical and translational research.

• Y-27632: Translational Leverage in Cytoskeletal Pathways

  2026-04-30

  This thought-leadership article dissects the mechanistic role of Y-27632, a selective ROCK inhibitor, in modulating cytoskeletal dynamics for translational research. Bridging stem cell biology and disease modeling—particularly in the context of long QT syndrome—this piece provides actionable protocol guidance, competitive context, and a forward-looking outlook. Differentiating itself from standard product pages, it draws on recent primary literature and scenario-driven resources to offer a strategic roadmap for researchers moving from bench to bedside.

• HSBP7 Depletion Rescues Titin-Linked Cardiomyopathy via Morp

  2026-04-29

  This study introduces the CARDIO imaging platform to systematically profile morphological and functional consequences of gene knockouts in human cardiomyocytes. Notably, HSBP7 depletion counteracts the contractile defects of titin loss-of-function cardiomyopathy, highlighting a new therapeutic avenue for heart failure.

• Strategic Innovation with 5-moUTP Firefly Luciferase mRNA

  2026-04-29

  This thought-leadership article explores the latest advances in 5-moUTP modified Firefly Luciferase mRNA as a transformative tool for translational research. Integrating mechanistic insights, comparative technology benchmarking, and actionable guidance, it builds a bridge from bench to preclinical innovation for researchers optimizing mRNA delivery, translation efficiency, and immune evasion. Evidence from current literature and operational studies is synthesized to guide strategic decision-making beyond standard product documentation.

• GW4064: Unlocking FXR Pathways for Translational Metabolic R

  2026-04-28

  This thought-leadership article explores GW4064, a non-steroidal FXR agonist, as a research tool for dissecting FXR signaling in metabolic and fibrotic disease models. We synthesize new mechanistic insights—highlighting the FXR/TLR4/ferroptosis axis—while offering strategic guidance for translational researchers implementing GW4064 in advanced experimental workflows. The article bridges deep mechanistic evidence, protocol recommendations, and evolving competitive intelligence to chart a visionary path for metabolic research.

• Capsazepine: TRPV1 Ion Channel Antagonist for Pain Research

  2026-04-28

  Capsazepine, a synthetic TRPV1 ion channel antagonist, enables high-precision dissection of nociception pathways and apoptosis sensitization mechanisms in vitro. With robust selectivity and workflow flexibility, it provides reproducible results for advanced pain and cancer research where classical agonist-antagonist models fall short.

• VE-822 ATR Inhibitor: Workflow Optimization in DDR Research

  2026-04-27

  VE-822 is a potent ATR inhibitor that enables precise DNA damage response (DDR) modulation and cancer chemoradiotherapy sensitization, especially in pancreatic ductal adenocarcinoma research. This article provides workflow enhancements, troubleshooting guidance, and practical integration strategies for maximizing VE-822’s selectivity and performance in advanced DDR assays.

• Gly-Gly-Phe-Gly (GGFG): Reliable Linker for Bioconjugation S

  2026-04-27

  This article explores real-world laboratory challenges in drug conjugation research and highlights how Gly-Gly-Phe-Gly (GGFG, SKU C8670) addresses key reproducibility and workflow needs. Drawing from peer-reviewed findings and protocol best practices, we detail why GGFG peptide stands out for antibody-drug conjugate development and peptide engineering.

• Patient-Derived Gastric Cancer Assembloids Enhance Drug Test

  2026-04-26

  This study introduces a patient-derived gastric cancer assembloid model that integrates tumor organoids with matched stromal cell subpopulations, closely mimicking the tumor microenvironment. The model reveals how stromal components influence gene expression and drug response, providing a more physiologically relevant platform for cancer research and personalized therapy development.

446 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page